Australian health supplements company Blackmores has expanded into soft-gel and tablet manufacturing with the acquisition of Catalent Australia’s world-class manufacturing facility in Braeside, Victoria, for a total of $53 million.
Blackmores’ CEO Alastair Symington said the facility is licensed to produce medicines by Australia’s Therapeutic Goods Administration as well as international regulators and would supply approximately half of the Group’s tablet and capsule requirements.
“The facility will support the Blackmores Group’s strong focus on growth and product innovation, with increased research and development capabilities, and provide greater control over production,” Mr Symington continued.
“The world-class product manufacturing facility and its almost 300 staff will enable the Group to be more responsive to changing market conditions.”
Blackmores’ intention to acquire Catalent was announced in April 2018, and the two companies have been locked in negotiations ‘to ensure a seamless transition’ ever since.
“Over the past 18 months, teams from Catalent Australia and Blackmores have worked closely to ensure a seamless transition,” said Mr Symington.
“We’ve invested in the systems and infrastructure to increase the site’s production capacity which will support our future growth.
Blackmores said the Braeside manufacturing facility will be fully operational as of today, supporting the extension of product registrations across markets in Asia and underpinning the Group’s ingredient sustainability and traceability program.